iBio Outlines Long-Acting Antibody Obesity Pipeline (IBIO-610 Activin E, IBIO-600 Myostatin, Amylin Series, PH-HFpEF Bispecific) at Wells Fargo Conference
iBio Inc. (NYSE American: IBIO) announced at the Wells Fargo 21st Annual Healthcare Conference in Boston (Chief Executive Officer Martin Brenner DVM PhD in a Tuesday September 8, 2026 fireside chat) a broadening push into obesity and cardiometabolic disease anchored on long-acting antibody programs and a thesis that the market will shift toward combination treatment with durable maintenance. Lead program IBIO-610 is a long-acting Activin E antibody designed for infrequent dosing with strong target blockade, following a July 2026 disclosure that a single dose achieved near-complete active Activin E inhibition through 8 weeks in obese non-human primates. IBIO-600 (myostatin inhibitor) has completed single-ascending-dose enrollment and is headed toward Q1 2027 data readout. iBio also has an amylin program with four molecules differentiated by receptor selectivity profiles and a bispecific molecule for pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The strategy is deliberately positioned as antibody-based rather than peptide-based to compete against MariTide, berobenatide, and the injectable-peptide GLP-1 class on dosing frequency and target-engagement duration.